Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· October 22, 2026
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
View original at finance.yahoo.comTelitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Vor Biopharma Annualized eGFR slope of -0.6 vs…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
At 104 weeks TELIGAN demonstrated substantial proteinuria reduction and durable kidney protection; annualized eGFR slope approaching zero, lower rates of kidney function deterioration and sustained proteinuria reductions after transition to every-other-week dosing reinforce telitacicept's clinical potential and add to evidence supporting dual BAFF/APRIL inhibition.
60% confidenceTELIGAN met the Stage B primary endpoint, with a statistically significant difference in annualized eGFR slope through 104 weeks versus placebo.
60% confidenceTelitacicept reduced the risk of confirmed ≥30% and ≥40% eGFR declines by 89% and 81%, respectively.
60% confidence
Cited in these Via News reports
- Biotech pipelines keep advancing on cash reserves while a risk-off tech market tightens the financing outlook →
- Biotech's clinical results are holding up while the AI money around it wobbles: what the European reader can verify →
- Europe's Biotech Cash Comes From Royalties and Hires While US Pipelines Hit Their Data Dates →
- Europe's Biotech Exposure Is Narrow but Real: A Swedish Royalty Stream Grows While the AI Funding Mood Sours →
- Europe's Biotech Footprint Is Thin in a Risk-Off Month, but BioArctic's Royalty Stream and Incyte's Cash Pile Show What Funding Stress Tests →
